ALK and non-small cell lung carcinoma: For BMs of NSCLC, some tyrosine kinase inhibitors, such as osimertinib, which targets EGFR-mutant NSCLC [82], and alectinib or brigatinib, which target ALK-positive NSCLC [83,84], have shown better CNS penetrance and disease control than traditional systemic chemotherapy [85].